Effects of liver fibrosis on verapamil pharmacokinetics in rats

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 3, 2008, Pages 287-294

  Chen, Man ^a   Xu, Dan ^a   Hu, Xiao Ling ^a   Wang, Hui ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Cytochrome P450; Intestine; Liver; Liver fibrosis; P glycoprotein; Pharmacokinetics; Verapamil

Indexed keywords

ALCOHOL; CARBON TETRACHLORIDE; CYTOCHROME P450 3A; FAT; GLYCOPROTEIN P; MESSENGER RNA; VERAPAMIL;

ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPID DIET; LIVER FIBROSIS; MALE; NONHUMAN; RAT; SINGLE DRUG DOSE; SMALL INTESTINE; UPREGULATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 CYP3A; INJECTIONS, INTRAVENOUS; LIVER CIRRHOSIS; MALE; P-GLYCOPROTEIN; RATS; RATS, WISTAR; VERAPAMIL;

EID: 39149128283     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04826.x     Document Type: Article

References (35)

1. Verbeeck RK, Horsmans Y. Effect of hepatic insufficiency on pharmacokinetics and drug dosing. Pharm. World Sci. 1998 20 : 183 92.
2. Friedman SL. Liver fibrosis: From bench to bedside. J. Hepatol. 2003 38 : 38 53.
3. Gould BA, Mann S, Kieso H, Subramanian VB, Raftery EB. The 24-h ambulatory blood pressure profile with verapamil. Circulation 1982 65 : 22 7.
4. Reichen J, Le M. Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver. J. Clin. Invest. 1986 78 : 448 55.
5. Reichen J, Hirlinger A, Ha HR, Sagesser S. Chronic verapamil administration lowers portal pressure and improved hepatic function in rats with liver cirrhosis. J. Hepatol. 1986 3 : 49 58.
6. Guo CY, Wu JY, Wu YB, Zhong MZ, Lu HM. Effects of endothelin-1 on hepatic stellate cell proliferation, collagen synthesis and secretion, intracellular free calcium concentration. World J. Gastroenterol. 2004 10 : 2697 700.
7. Xu D, Wu Y, Liao ZX, Wang H. Protective effect of verapamil on multiple hepatotoxic factors-induced liver fibrosis in rats. Phamacol. Res. 2007 55 : 280 6.
8. Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N. Verapamil disposition in liver disease and intensive-care patients: Kinetics, clearence, and apparent blood flow relationships. Clin. Pharmacol. Ther. 1981 29 : 27 34.
9. Finucci GF, Padrini R, Piovan D et al. Verapamil pharmacokinetics and liver function in patients with cirrhosis. Int. J. Clin. Pharmacol. Res. 1988 8 : 123 6.
10. Kaminsky LS, Zhang QY. The small intestine as a xenobiotic-metabolizing organ. Drug Metab. Dispos. 2003 31 : 1520 5.
11. Vincent JW, Laurent S, Leslie ZB. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. 2001 46 : 89 102.
12. Ward KW, Stelman GJ, Morgan JA, Smith BR. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metab. Dispos. 2004 32 : 172 7.
13. Takara K, Ohnishi N, Horibe S, Yokoyama T. Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAs in rat small intestine. Drug Metab. Dispos. 2003 31 : 1235 9.
14. Zhou S, Chan E, Lim LY et al. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr. Drug Metab. 2004 5 : 415 42.
15. Peterson TC, Hodgson P, Fernandez-Salguero P, Neumeister M, Gonzalez FJ. Hepatic fibrosis and cytochrome P450: Experimental models of fibrosis compared to AHR knockout mice. Hepatol. Res. 2000 17 : 112 25.
16. Wang H, Chen M, Liao ZX. Changes of liver xenobiotic-metabolizing functiuon at the different status of hepatic injury. Chin. Pharmacol. Bull. 2004 20 : 772 5.
17. Lau-Cam CA, Piemontese D. Simplified reversed-phase HPLC method with spectrophotometric detection for the assay of verapamil in rat plasma. J. Pharm. Biomed. Anal. 1998 16 : 1029 35.
18. Ibrahim RB, Wilson JG, Thorsby ME, Edwards DJ. Effect of buprenorphine on CYP3A activity in rat and human liver microsomes. Life Sci. 2000 66 : 1293 8.
19. Shmizu Y, Kusunose E, Kikuta Y, Arakawa T, Ichihara K, Kusunose M. Purification and characterization of two new cytochrome P-450 related to CYP2C subfamily from rabbit small intestine microsomes. Biochim. Biophys. Acta 1997 1339 : 268 76.
20. Yoo JS, Smith TJ, Ning SM, Lee MJ, Thomas PE, Yang CS. Modulation of the levels of cytochrome P450 in rat liver and lung by dietary lipid. Biochem. Pharmacol. 1992 43 : 2535 42.
21. Kwan P, Sills GJ, Butler E, Gant TW, Brodie MJ. Differential expression of multidrug resisitance genes in naïve rat brain. Neurosci. Lett. 2003 339 : 33 6.
22. Gabrielson JL, Weiner DL. Methodology for pharmacokinetic/pharmacodynamic data analysis. Pharm. Sci. Technol. Today 1999 2 : 244 52.
23. Wilkinson GR, Shand DG. Commentary: A physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 1975 18 : 377 90.
24. Bae SK, Lee SJ, Kim JW, Kim YH, Kim SG, Lee MG. Effects of acute renal failure on the pharmacokinetics of oltipraz in rats. J. Pharm. Sci. 2004 93 : 2353 63.
25. McGowan FX, Reiter MJ, Pritchett EL, Shand DG. Verapamil plasma binding: Relationship to alpha 1-acid glycoprotein and drug efficacy. Clin. Pharmacol. Ther. 1983 33 : 485 90.
26. Fouad FM, Mamer OA, Shahidi F. Acute-phase response in rat to carbon tetrachloride-azathioprine induced cirrhosis and partial hepatectomy of cirrhotic liver. J. Toxicol. Environ. Health 1996 47 : 601 15.
27. Guo Y, Wang H, Zhang C. Establishment of rat precision-cut fibrotic liver slice technique and its application in verapamil metabolism. Clin. Exp. Pharmcol. Physiol. 2007 34 : 406 13.
28. Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br. J. Clin. Pharmacol. 1999 47 : 545 52.
29. Wacher VJ, Wu C-Y, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 1995 13 : 129 34.
30. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 1998 87 : 1322 30.
31. Benet LZ, Wu CY, Hebert MF, Wacher VJ. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J. Control. Release 1996 39 : 139 43.
32. Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin. Pharmacol. Ther. 2006 79 : 218 30.
33. Laffont CM, Toutain PL, Alvinerie M, Bousquet-Melou A. Intestinal secretion is a major route for parent ivermectin elimination in the rat. Drug Metab. Dispos. 2002 30 : 626 30.
34. Lown KS, Mayo RR, Leichtman AB et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 1997 62 : 248 60.
35. Saitoh H, Aungst BJ. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm. Res. 1995 12 : 1304 10.